ARL11

Across TCGA pan-cancer cohorts, ARL11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARL11 data layer compared with 19 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARL11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL11 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where ARL11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.368	0.737	.011	12	view →
PDAC	OS	Median	All	0.213	0.684	.047	3	view →
LSCC	DFS	Quartile	All	1.000	0.890	.031	3	view →
GBM	OS	Median	All	0.365	0.632	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARL11–LUAD (DFS)

Open the LUAD breakdown →